Netherlands Pharmaceuticals and Healthcare Report Q3 2012


While the Netherlands is a low risk market from the point of view of multinational drugmakers, the country’s modest per capita expenditure on pharmaceuticals relative to other Western Europe countries remains an issue. A further challenge facing drugmakers is cost-containment, which can only intensify as the Netherlands enters a phase of slower economic growth. 
Headline Expenditure Projections
Pharmaceuticals: EUR6.70bn (US$9.31bn) in 2011 to EUR6.54bn (US$8.44bn) in 2012; -2.4% decline in local currency terms and -9.4% decline in US dollar terms. 
Healthcare: EUR63.32bn (US$88.02bn) in 2011 to EUR65.09bn (US$83.96bn) in 2012; +2.8% growth in local currency terms and -4.60% growth in US dollar terms. 
Medical devices: EUR11.41bn (US$15.86bn) in 2011 to EUR11.77bn (US$15.18bn) in 2012; 3.2% growth in local currency terms and -4.2% in US dollar terms 
Business Environment Rating: The Netherlands’ composite score in our latest Pharmaceutical Risk/Reward Ratings (RRRs) matrix for Western Europe is unchanged from the previous quarter. The figure of 64.2 out of the maximum 100 ranks it seventh out of the 10 markets in the matrix. Despite a developed healthcare market, the Netherlands’ overall ranking continues to be propped up by its favourable risk variable, with the rewards negatively impacted by costcontainment, in combination with patent expirations. 
Key Trends And Developments • In April 2012, a Chinese traditional medicine was authorized for sale in a European market for the first time – Di'ao Xin Xue Kang, a well-known herbal medicine produced by the Chengdu based Di'ao Group, received marketing authorization from the Medicines Evaluation Board of the Netherlands, making it the first Chinese traditional drug to be identified as a therapeutic medicine in the European Union. 
BMI Economic View: The Dutch economy's exposure to the eurozone sovereign debt crisis continues to weigh heavily on economic activity and confidence. As a result, our weaker outlook for domestic demand means we now forecast the economy to contract by 0.3% in 2012, from our previous 0.4% real GDP growth forecast. Weak longer-term economic activity in the eurozone is also set to drag on the Netherland's growth trajectory and we forecast economic growth to average a weak 1.1% to 2016.. 
BMI Political View: The stability of Netherlands’ Prime Minister Mark Rutte's minority government is likely to come under increased pressure in 2012, as the negotiations over Dutch involvement in eurozone bailout packages expose rifts between the coalition parties. In particular, with the far-right Party For Freedom gaining momentum, a coalition breakdown cannot be precluded, which could potentially stall some of the government’s fiscal austerity measures
 Published : May 2012                  No. of Pages : 80                      Price:US$1175
Buy Now
Table of Content
 Executive Summary . 5
SWOT Analysis 6
Netherlands Pharmaceuticals And Healthcare Industry SWOT . 6
Netherlands Political SWOT .. 7
Netherlands Economic SWOT 7
Netherlands Business Environment SWOT. 8
Pharmaceutical Risk/Reward Ratings ... 9
Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q312 11
Rewards ... 11
Risks . 12
The Netherlands – Market Summary ... 13
Regulatory Regime 14
Regulatory Developments 15
Intellectual Property Regime ... 15
Pricing And Reimbursement Regime 16
Industry Developments . 19
Epidemiology ... 19
Healthcare Sector 20
Healthcare Funding . 21
Health Insurance.. 21
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 . 22
Healthcare Insurance Developments ... 23
Research And Development Sector .. 24
Clinical Trials .. 27
Medical Devices Industry . 27
Medical Devices Industry Developments . 27
Industry Forecast Scenario .. 29
Overall Market Forecast .. 29
Table: Pharmaceutical Sales Indicators 2008-2016 30
Healthcare Market Forecast 31
Table: Healthcare Expenditure Indicators 2008-2016 32
Table: Healthcare Governmental Indicators 2008-2016. 33
Table: Healthcare Private Indicators 2008-2016 33
Key Growth Factors – Macroeconomic 34
NETHERLANDS – ECONOMIC ACTIVITY 37
Prescription Drug Market Forecast . 38
Table: Prescription Drug Sales Indicators 2008-2016 38
Patented Drug Market Forecast .. 39
Table: Patented Drug Market Indicators 2008-2016 ... 40
Generic Drug Market Forecast . 41
Table: Generic Drug Sales Indicators 2008-2016 ... 42
OTC Medicine Market Forecast .. 43
Table: OTC Medicine Sales Indicators 2008-2016 .. 45
Pharmaceutical Trade Forecast ... 46
Table: Exports and Imports Indicators 2008-2016 .. 46
Medical Devices Market Forecast 48
Table: Medical Devices Sales Indicators 2008-2016 ... 49
Other Healthcare Data 50
Key Risks To BMI’s Forecast Scenario 50
Competitive Landscape 51
Pharmaceutical Industry .. 51
Company Activities .. 51
Pharmaceutical Wholesale Sector 53
Pharmaceutical Retail Sector .. 54
Wholesale And Retail Sector Developments . 54
Company Profiles .. 55
Local Manufacturers . 55
DSM . 55
Qiagen . 57
Pharming Group .. 59
Multinational Manufacturers 61
Merck & Co . 61
Pfizer 63
GlaxoSmithKline .. 65
Sanofi ... 67
Novartis ... 69
Demographic Data . 70
NETHERLANDS – Population By Age Group . 71
NETHERLANDS – Population By Age Group . 71
NETHERLANDS – Key Population Ratios ... 72
NETHERLANDS – Rural and Urban Population . 73
Glossary . 74
BMI Methodology ... 76
How We Generate Our Pharmaceutical Industry Forecasts 76
Pharmaceuticals Business Environment Ratings . 77
Risk/Reward Ratings Methodology .. 77
Ratings Overview . 77
Table: Pharmaceutical Business Environment Indicators 78
Weighting . 79
Table: Weighting Of Components 79
Sources 79
Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q312 . 11
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 . 22
Table: Pharmaceutical Sales Indicators 2008-2016 . 30
Table: Healthcare Expenditure Indicators 2008-2016 . 32
Table: Healthcare Governmental Indicators 2008-2016. 33
Table: Healthcare Private Indicators 2008-2016 . 33
Table: Prescription Drug Sales Indicators 2008-2016 . 38
Table: Patented Drug Market Indicators 2008-2016 . 40
Table: Generic Drug Sales Indicators 2008-2016 . 42
Table: OTC Medicine Sales Indicators 2008-2016 . 45
Table: Exports and Imports Indicators 2008-2016 . 46
Table: Medical Devices Sales Indicators 2008-2016 . 49
Table: Pharmaceutical Business Environment Indicators . 78
Table: Weighting Of Components . 79


Comments

  1. V. K. Sinha25 August 2012 at 11:07

    Food Recruitment
    Thanks for your great information, the contents are quiet interesting.I will be waiting for your next post.

    ReplyDelete

Post a Comment

Popular posts from this blog

MarketReportsOnline: Indonesia Rubber Industry Analysis

Image
MarketReportsOnline.com adds "Assessment of Indonesia's Rubber Industry Analysis 2015" report to its research store. The global market is currently in its fourth year of surplus of natural rubber. The excess supply situation has caused stocks to pile high and prices are falling steadily. It is expected that global surplus by the year 2020 will be approximately 1 million tons of natural rubber and 3 million tons of synthetic rubber.World demand for natural rubber, which is primarily used to manufacture tires, is cooling down due to the economic downturn in China. Asia accounts for 93% of the world natural rubber production with Thailand being the largest producer followed by Indonesia and Vietnam. Other large rubber producers in the region include India, China and Malaysia. Complete report available at http://www.marketreportsonline.com/442401.html .    China is the world’s largest consumer of natural rubber followed by India and the United States. In
Read more

Latest Guide to Chinese Pharmaceutical GMP Regulations

Image
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US$246 billion), an increase of 7.08 fold over 2000 level. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural will grow the Chinese drug market with a growth rate over 25 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015. Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which not only gave a fillip to the imported drugs from overseas pharmaceutical manufacturers but also attracted overseas investors to establish the foreign investment enterprises, including “Sino-foreign equity joint ventures (EJV)”,
Read more

Construction in Bahrain – Key Trends and Opportunities to 2015

Image
Synopsis This report provides detailed market analysis, information and insights into the Bahrain construction market, including: • Top level overview of the construction industry in Bahrain • Current, historic and forecast market value and trends of individual markets and categories supported by detailed descriptions of individual markets in the industry • Profiles of the top construction companies in Bahrain • Profiles of the ten largest construction projects in Bahrain Summary The Bahrain construction industry had been growing at a robust pace prior to the onset of the global financial crisis. This growth had been fuelled by the country’s long-term efforts to diversify its economy, efforts which have led to the emergence of Bahrain as the financial capital of the Middle East and have also led to many multinational companies establishing their Middle Eastern bases in the country, attracted by favorable tax policies and the country’s strategic location in the center of the Gulf
Read more